Navigation Links
New Study Published: Lactobacillus reuteri Prodentis Effective in the Treatment of Periodontitis
Date:11/10/2010

New Study Published: Lactobacillus reuteri Prodentis Effective in the Treatment of Periodontitis -- STOCKHOLM, November 10, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services, Clinical Trials & Medical Discoveries Click to view news release full screen  

New Study Published: Lactobacillus reuteri Prodentis Effective in the Treatment of Periodontitis

 
Download image

STOCKHOLM, November 10, 2010 /PRNewswire-FirstCall/ -- The study shows that L. reuteri Prodentis acts synergistically with standard treatment (scaling and root plaining, SRP) to significantly reduce probing pocket depth (PPD) and clinical attachment level (CAL) which are the two most important parameters to assess the severity of periodontitis. Furthermore L. reuteri Prodentis reveals - as the first probiotic ever - significant reductions of three different pathogens in patients with chronic periodontitis. The study also confirms the anti-inflammatory effects of L. reuteri Prodentis on gum inflammation (gingivitis).

(Photo: http://www.newscom.com/cgi-bin/prnh/20101110/418565 )

Chronic periodontitis occurs in up to 40 % of the adult population. The standard treatment aims at removing plaque in the dental pockets to reduce the periodontal pathogens and thereby prevent disease progression.

Thirty chronic periodontitis patients were included in the double blind, randomized, placebo-controlled clinical trial that lasted for 42 days. On day 0 the teeth in one half of the mouth were treated with SRP whereas the teeth in the other half were left untreated. From day 21 to day 42 the patients were supplemented with either L. reuteri Prodentis lozenges (1X108 CFU DSM 17938 and 1x108 CFU ATCC PTA 5289) or placebo lozenges twice daily.

The result showed that a combination of L. reuteri Prodentis and SRP was significantly better than all other modalities in reducing gingivitis and plaque. Moreover, L. reuteri Prodentis, either alone or following SRP, significantly reduced the pathogens Aggregibacter actinomycetemcomitans, Porphyromonas gingivalis and Prevotella intermedia by up to 90 % as compared to the treatments that did not include L. reuteri Prodentis. The combination of L. reuteri Prodentis and SRP was also significantly better than SPR alone in reducing both PPD (p<0.001) and CAL (p<0.001), see attachment.

- This short-term study proves that L. reuteri Prodentis by itself has a powerful effect on the pathogens of periodontitis and that the combination of L. reuteri Prodentis and SRP synergistically improves both PPD and CAL, says Professor Vandana at the College of Dental Science in Davangere, India. - The results strengthen L. reuteri Prodentis position as a proven treatment option for patients with periodontal disease, says Peter Rothschild, President, BioGaia AB.

The results of the study were published online on the 2nd of November 2010 in the Journal of Oral Microbiology, doi: 10.3402/jom.v2i0.5344. The study can be accessed at: http://www.journaloforalmicrobiology.net/index.php/jom/article/view/5344

BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. http://www.biogaia.com


'/>"/>
SOURCE BioGaia
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD
2. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
3. Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years
4. New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement
5. Sermo Study Shows 63% of Physicians Would Utilize New Gout Treatments
6. Study Published This Week in Alzheimers & Dementia: The Journal of the Alzheimers Association Shows that Algal DHA Improved Memory and Learning in Healthy Adults Age 55 and Older
7. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
8. Allegheny General Hospital Study Suggests Use of Image Guided Intensity Modulated Radiation Therapy Reduces Risk of Impotency in Men Needing Radiation after Prostate Cancer Surgery
9. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
10. Hologic Announces Long-term, Five-year Results from MammoSite® ASBS Registry Study
11. Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... YORK and GENEVA , ... announced on World Tuberculosis Day revitalizes efforts to develop ... On World Tuberculosis Day, TB Alliance and ... for the clinical development of sutezolid, an antibiotic drug ... sublicense pertains to the development of sutezolid in combination ...
(Date:3/23/2017)... MOBILE, Ala. , March 23, 2017 Mosaic Life Care, based in ... automate the patient registration process across its network of 58 clinics, located in 22 ... constantly seeking new and innovative ways to improve the delivery of health care to ... Continue Reading ... Mosaic Life Care St. Joseph ...
(Date:3/23/2017)... 2017  Transportation Insight, a multi-modal lead logistics solutions ... management firm with expertise serving clients in the food ... Zaffarano was named a 2017 Food Logistics ... the only publication exclusively dedicated to covering the movement ... "Rick has brought to Transportation Insight a wealth ...
Breaking Medicine Technology:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... The ... Quest Awards . The annual awards, now in their 12th year, are among ... selects the winners. , In 2016, the awards were retooled to recognize achievements in ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mlynarek Insurance Agencies, a Detroit ... business owners across eastern Michigan, is connecting with the Oxford/Orion FISH Food Pantry ... , The Oxford/Orion FISH Food Pantry works to ensure homeless, hungry, and underprivileged ...
(Date:3/24/2017)... ... March 24, 2017 , ... Northridge dentists, Dr. ... for sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, ... obstructive type, is increasingly being treated at dental offices with newly developed procedures ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health (“GH”) ( ... patients for colonoscopy at the HyGIeaCare® Center that is to be located adjacent ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: a dauntless and ... “End Time GPS” is the creation of published author, Wesley Gerboth, a World ... military munitions and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God ...
Breaking Medicine News(10 mins):